Drug Shortage Report for TAZORAC
| Report ID | 144130 |
| Drug Identification Number | 02230784 |
| Brand name | TAZORAC |
| Common or Proper name | tazarotene gel 0.05% |
| Company Name | ALLERGAN INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | TAZAROTENE |
| Strength(s) | 0.05% |
| Dosage form(s) | GEL |
| Route of administration | TOPICAL TOPICAL |
| Packaging size | 30g |
| ATC code | D05AX |
| ATC description | ANTIPSORIATICS FOR TOPICAL USE |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-08-13 |
| Actual start date | |
| Estimated end date | 2021-11-30 |
| Actual end date | 2021-11-26 |
| Shortage status | Resolved |
| Updated date | 2021-12-23 |
| Company comments | Drug has been discontinued |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2021-12-23 | English | Compare |
| v5 | 2021-11-26 | French | Compare |
| v4 | 2021-11-26 | English | Compare |
| v3 | 2021-08-14 | English | Compare |
| v2 | 2021-08-13 | French | Compare |
| v1 | 2021-08-13 | English | Compare |
Showing 1 to 6 of 6